Rubrum Advising

I’m thrilled to share a new piece I co-authored in JAMA, Journal of the American Medical Association “Why Evidence Generation Should Matter to Payers and How They Can Help.” This work explores the influence of data strategy in policy decisions and clinical practice as well as payers’ crucial role in enhancing post market evidence generation.   A huge thank you to my esteemed colleagues Ali B. Abbasi, Lesley Curtis, Ph.D., and Robert Califf for including me to write on this important topic.   #Healthcare #ClinicalTrials #EvidenceGeneration #MedicalResearch #HealthcarePolicy #Payers #PublicHealth Rubrum Advising

We are hiring! We have an amazing and growing team at Rubrum Advising. If you or anyone you know is looking to join our firm, don't hesitate to reach out.

I am so looking forward to attending @DeviceTalks Boston on May 2nd with the Rubrum Advising team and hearing more about the exciting developments in the #medicaldevice space. I'm especially interested in hearing how medical device developers are generating data to not only support FDA approval and CMS coverage, but also promote evidence-based medicine. I've captured my thoughts on the topic, including my experience working with my former CMS colleagues on the TCET pathway, in this JAMA Cardiology Opinion piece.   #dtboston2024 #medtech #medicaldevices   https://lnkd.in/eJiWCQRN  

The pace of improvements in the diagnosis and treatment of rare diseases has never been so exciting with the development of enhanced clinical decision support through AI and gene therapy.  The ability to access these advancements will be impacted by regulations across federal Agencies.  The recent report from Alexion's Rare Conversation and Policy forum was just released and included my own and my colleague Hilary Marston’s comments regarding the FDA and CMS implications in this space.    https://lnkd.in/egNQ_Ss3  Centers for Medicare & Medicaid Services. FDA Alexion Pharmaceuticals, Inc. #genetherapy #breakthroughtech #healthcareinnovation #patientcare Rubrum Advising

Excited for my new opinion piece in MedPage Today discussing collaborative efforts between FDA and Centers for Medicare & Medicaid Services as well as the imperative use of evidence generation and coordination amongst the Agencies. In the piece, I discuss the need for closer collaboration and data exchange between FDA and Centers for Medicare & Medicaid Services, including using the principles of TCET and active feedback channels to facilitate patient access to breakthrough technologies. Rubrum Advising Bipartisan Policy Center #Healthcare #Innovation #FDA #CMS https://lnkd.in/gMqAvMr7

Rubrum Advising is excited to announce that we are hiring for our fellowship program! We are looking for individuals who are passionate about healthcare and healthcare innovation to join our team and serve on our broad portfolio of engagements. If you or someone you know is interested, please view the job description below and apply directly through LinkedIn. #healthcare #healthcareinnovation #healthcareconsulting #fellowship #internships Kurt Herzer Matthew Fleisher

It is a true pleasure to welcome Kurt Herzer as our newest Principal at Rubrum Advising. Kurt brings a wealth of expertise on modernizing technology and data infrastructure as well as developing new platforms and applications for advanced analytics, machine learning, and artificial intelligence across the world’s largest collections of healthcare data. I was proud to work with him at CMS and I know together, we can help further healthcare for all patients. #healthcareinnovation #healthtech #healthcarestartups #healthcaredata #publichealth @rubrumadvising